In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an
initial evaluation for COVID-19 status, medical history, and symptom assessment, patients
will receive either 2.5 mg/day of ramipril or placebo. Patients' symptoms and study endpoints
will be monitored at regular intervals. After 14 days, patients will undergo a laboratory
assessment and an end-of-treatment follow-up visit at day 28. The primary endpoints of
successful therapy will be improved survival, reductions in ICU admissions, and/or reductions
in use of mechanical ventilator support.